Marta Giner-Asins leads the team at Norton Rose Fulbright, which advises a diverse client base of biological laboratories, healthcare providers, and international pharma companies. The group handles a number of mandates, including drug market access and pricing, and anti-gift-related matters relating to hospital partnerships. Giner-Asins is noted for her antitrust expertise, having represented numerous pharma companies before both French and European competition Authorities, and in dawn raids. Technology and IP specialist Nadège Martin is noted for her expertise in the creation of health data lakes, in addition to regulatory compliance with CNIL standards, while Christian Dargham handles product liability disputes and investigations. Marion Roquette-Pfister left the firm in early 2024.
Testimonials
Collated independently by Legal 500 research team.
‘The team is relentless in their dedication to their clients. Diverse teams, provided their services with care and were pragmatic.’
Key clients
- Pfizer
- Sanofi
- Abbott
- Medtronic
- SYNLAB
- Ramsay Santé
- Embecta
Work highlights
- Advised Ramsay Santé as to the eligibility of the debts to be assigned by a pool of circa 50 entities of the group Ramsay Santé for an amount of circa EUR 150m held on the French Health Authorities as part of the COVID-19 revenues compensation scheme put in place by the French Government for the benefit of private acute care groups to such assignment for financing purposes to a private bank (Natixis).
- Assisted PFIZER France in the negotiations with the French public authorities for the implementation of a new legal system for the marketing, pricing and reimbursement of gene therapies in France.
- Advised SYNLAB, an international leading group of biological laboratories, in the context of negotiations with the French Social Security Agency regarding invoicing controls and we especially assisted them in drafting a transactional protocol with the French Health Insurance.
Practice head
The lawyer(s) leading their teams.
Marta Giner-Asins